AGVEX
Price
$31.18
Change
-$0.03 (-0.10%)
Updated
Jul 2 closing price
Net Assets
21.48B
CWICX
Price
$80.52
Change
-$0.06 (-0.07%)
Updated
Jul 2 closing price
Net Assets
159.53B
Interact to see
Advertisement

AGVEX vs CWICX

AGVEX vs CWICX Comparison Chart in %
View a ticker or compare two or three
VS
AGVEX vs. CWICX commentary
Jul 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGVEX is a Hold and CWICX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CWICX has more cash in the bank: 160B vs. AGVEX (21.5B). AGVEX pays higher dividends than CWICX: AGVEX (0.71) vs CWICX (0.66). AGVEX was incepted earlier than CWICX: AGVEX (7 years) vs CWICX (24 years). CWICX (1.52) is less costly to investors than AGVEX (0.82). CWICX is a more actively managed with annual turnover of: 44.00 vs. AGVEX (35.00). AGVEX (250) and CWICX (250) have matching initial minimum investment requirements. AGVEX annual gain was more profitable for investors over the last year : 19.41 vs. CWICX (14.79). AGVEX return over 5 years is better than : 52.73 vs. CWICX (30.00).
AGVEXCWICXAGVEX / CWICX
Total Expense Ratio0.821.5254%
Annual Report Gross Expense Ratio0.821.5254%
Fund Existence7 years24 years-
Gain YTD10.17713.75874%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets21.5B160B13%
Annual Yield % from dividends0.710.66109%
Returns for 1 year19.4114.79131%
Returns for 3 years56.7044.86126%
Returns for 5 years52.7330.00176%
Returns for 10 yearsN/A104.70-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRBRX218.095.52
+2.60%
Franklin Biotechnology Discovery R6
VEUSX111.822.10
+1.91%
Vanguard European Stock Admiral
GSIKX25.450.40
+1.60%
Goldman Sachs International Eq Inc Instl
MUOAX34.91-0.03
-0.09%
Morgan Stanley Instl US Core A
BUFMX14.26-0.24
-1.66%
Buffalo Mid Cap Growth